Post-market Clinical Follow-up Study for a CE Marked Wound Care Product (FibDex®)
← catalyst calendarSponsored by UPM-Kymmene Corporation (industry) · UPM.HE — their whole pipeline →. With Helsinki University Central Hospital.
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
UPM Kymmene Oyj announced on April 2, 2025, the closure of Biomedicals business. As a result, FibDex manufacturing and sales will discontinue. The premature termination is due to business decision, not related to any safety concerns of FibDex.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-15 | actual | When the study began enrolling |
| Primary completion | 2025-04-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-30 | actual | The whole study's end, after follow-up |
| First posted | 2022-12-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Skin Transplantation
Interventions
- Device: FibDex®
- Device: Suprathel
- Device: Aquacel Foam
Primary outcomes
what the primary-completion date above is the date OFPermalink · UPM.HE's whole pipeline · Catalyst calendar · Every registered study · What changed